Wikidata

(Q63817054)

English

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

clinical trial

In more languages

Statements

title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus®) and Peginterferon Alfa 2a (Pegasys®) in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS-US-196-0123) (English)
0 references
medical condition
hepatitis A
0 references
hepatitis
0 references
hepatitis C
0 references
country
Austria
0 references
Belgium
0 references
Canada
0 references
Czech Republic
0 references
France
0 references
Germany
0 references
Italy
0 references
Poland
0 references
Spain
0 references
United Kingdom
0 references
start time
October 2010
0 references
end time
January 2013
0 references
number of participants
324
0 references
minimum age
18 year
0 references
maximum age
70 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q63817054&oldid=1857408589"